Thursday 21 November 2024

The Pharma Letter Podcast — Episode 22 — A new way to innovate, from Flagship Pioneering

Biotechnology
Simon Wentworth
20 April 2023
episode22-big-1

More on this story...

Pharmaceutical
Novo Nordisk wraps up another weight management deal
9 May 2024
Biotechnology
Empress Therapeutics emerges from stealth with $50 million financing
21 June 2023
Biotechnology
Avalyn picks up $175 million in Series C financing
28 September 2023
Pharmaceutical
The Pharma Letter Podcast — Episode 25 — The need for change for major depressive disorder patients
10 October 2023


Companies featured in this story

More ones to watch >


Today's issue

EC approval for Pfizer’s Hympavzi
Biotechnology
EC approval for Pfizer’s Hympavzi
20 November 2024
Biotechnology
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Pharmaceutical
Ascentage's lisaftoclax accepted for priority review in China
20 November 2024
Biosimilars
Xbrane and Intas to jointly develop Opdivo biosimilar
20 November 2024
Pharmaceutical
Chris Boshoff takes on new role at Pfizer
20 November 2024
Biotechnology
Two Neds better than one in Jupiter’s world of moons
20 November 2024
Pharmaceutical
Cytokinetics and Bayer ink deal for aficamten in Japan
20 November 2024

Company Spotlight

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.




More Features in Biotechnology

EC approval for Pfizer’s Hympavzi
20 November 2024
Flagship reveals new agreements under Pfizer link-up
20 November 2024
Two Neds better than one in Jupiter’s world of moons
20 November 2024
JAK inhibitors redefining atopic dermatitis treatment
20 November 2024


Copyright © The Pharma Letter 2024   |   Headless Content Management with Blaze